Insulin degludec
- Generic Name
- Insulin degludec
- Brand Names
- Ryzodeg, Tresiba, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 844439-96-9
- Unique Ingredient Identifier
- 54Q18076QB
- Background
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. ...
- Indication
Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 179
- Registration Number
- NCT04663282
- Locations
- 🇺🇸
Torrance Clinical Research Institute Inc, Lomita, California, United States
🇦🇺Core Research Group Pty Ltd, Brisbane, Queensland, Australia
🇦🇺The Royal Melbourne Hospital, Melbourne, Victoria, Australia
Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose
- Conditions
- Interventions
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 59
- Registration Number
- NCT04623086
- Locations
- 🇺🇸
University of Washington Medicine Diabetes Institute at South Lake Union, Seattle, Washington, United States
Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 331
- Registration Number
- NCT04588259
- Locations
- 🇨🇳
Chongqing University Three Gorges Hospital, ChongQing, Chongqing, China
🇨🇳Suzhou Municipal Hospital, Suzhou, Jiangsu, China
🇨🇳Nanjing Jiangning Hospital, Nanjing, Jiangsu, China
A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 31
- Registration Number
- NCT04585776
- Locations
- 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States
🇺🇸HealthPartners Institute dba International Diabetes Center, Minneapolis, Minnesota, United States
A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 68
- Registration Number
- NCT04569994
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
- Conditions
- Interventions
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 60
- Registration Number
- NCT04538352
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
A Study of LY3209590 in Participants With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 266
- Registration Number
- NCT04450407
- Locations
- 🇦🇹
Klinik Landstraße, Vienna, Austria
🇺🇸Diabetes and Thyroid Center of Fort Worth, Fort Worth, Texas, United States
🇺🇸Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States
A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 278
- Registration Number
- NCT04450394
- Locations
- 🇦🇷
CEMEDIC, Buenos Aires, Argentina
🇵🇱Centrum Kliniczno-Badawcze, Elblag, Poland
🇵🇱Gabinety TERPA, Lublin, Poland
A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Russia
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 494
- Registration Number
- NCT04315688
- Locations
- 🇷🇺
Novo Nordisk Investigational Site, Vyksa, Russian Federation
A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT04276428
- Locations
- 🇯🇵
Yokohama Minoru Clinic, Yokohama, Japan
🇯🇵Clinical Research Hospital Tokyo, Shinjuku-ku, Jp-13, Japan
🇯🇵P-one clinic, Hachioji, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.